Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs

被引：36
作者：
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Mikhailidis, Dimitri P. [2 ]
机构：
[1] Aristotle Univ Thessaloniki, Propedeut Dept Internal Med 2, Med Sch, Hippocrat Hosp, Thessaloniki, Greece
[2] UCL, Dept Clin Biochem, Med Sch, Royal Free Hosp Campus, London, England
来源：
JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2017年 / 31卷 / 03期
关键词：
CARDIOVASCULAR-DISEASE; URIC-ACID; RISK; NAFLD;
D O I：
10.1016/j.jdiacomp.2016.12.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：521 / 522
页数：2
相关论文
共 20 条
[1]   Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].
Armstrong, Matthew James ;
Gaunt, Piers ;
Aithal, Guruprasad P. ;
Barton, Darren ;
Hull, Diana ;
Parker, Richard ;
Hazlehurst, Jonathan M. ;
Guo, Kathy ;
Abouda, George ;
Aldersley, Mark A. ;
Stocken, Deborah ;
Gough, Stephen C. ;
Tomlinson, Jeremy W. ;
Brown, Rachel M. ;
Huebscher, Stefan G. ;
Newsome, Philip N. .
LANCET, 2016, 387 (10019) :679-690
[2]   Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes? [J].
Athyros, Vasilios G. ;
Katsiki, Niki ;
Karagiannis, Asterios .
CURRENT VASCULAR PHARMACOLOGY, 2016, 14 (06) :494-497
[3]   Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed? [J].
Athyros, Vasilios G. ;
Katsiki, Niki ;
Mikhailidis, Dimitri P. .
CURRENT VASCULAR PHARMACOLOGY, 2016, 14 (04) :313-315
[4]   Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update [J].
Athyros, Vasilios G. ;
Tziomalos, Konstantinos ;
Katsiki, Niki ;
Doumas, Michael ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (22) :6820-6834
[5]   Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis [J].
Carbone, Laura J. ;
Angus, Peter W. ;
Yeomans, Neville D. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (01) :23-31
[6]   EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease [J].
European Association for the Study of the Liver .
DIABETOLOGIA, 2016, 59 (06) :1121-1140
[7]   Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes [J].
Guo, Kaifeng ;
Zhang, Lei ;
Lu, Junxi ;
Yu, Haoyong ;
Wu, Mian ;
Bao, Yuqian ;
Chen, Haibing ;
Jia, Weiping .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (01) :80-85
[8]   Non-alcoholic fatty liver disease and dyslipidemia: An update [J].
Katsiki, Niki ;
Mikhailidis, Dimitri P. ;
Mantzoros, Christos S. .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08) :1109-1123
[9]   The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update [J].
Katsiki, Niki ;
Athyros, Vasilios G. ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (22) :3665-3674
[10]   Uric Acid and Diabetes: Is there a Link? [J].
Katsiki, Niki ;
Papanas, Nikolaos ;
Fonseca, Vivian A. ;
Maltezos, Efstratios ;
Mikhailidis, Dimitri P. .
CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (27) :4930-4937
12